Antagon

Antagon Therapeutics is a Swiss biotechnology company specializing in the development of microRNA-targeting therapies for cancer and fibrotic diseases. The company's lead candidate, ANT-101, is an antisense oligonucleotide that selectively inhibits microRNA-155, a known oncogene and driver of inflammation. Antagon's approach focuses on restoring normal cellular function by modulating dysregulated RNA pathways in high-unmet-need indications like cutaneous T-cell lymphoma. Founded as a spin-off from ETH Zurich, the company leverages deep expertise in RNA chemistry and biology to advance its pipeline of precision medicines. The firm is backed by a syndicate of leading European life science investors and aims to expand its platform to target other disease-relevant microRNAs.